Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week Low - Time to Sell?

Key Points

• Kailera Therapeutics shares fell to a new 52-week low of $13.32 and were last trading at $13.45, down from the previous close of $13.75.
• The company reported a quarterly loss of $1.09 per share, missing analysts’ expected loss of $0.74; analysts project a full-year loss of $3.89 per share.
• Despite the weak results and mixed ratings—including recent sell ratings—Kailera retains a “Moderate Buy” consensus and a $42.75 average price target, while several institutional investors established new positions.

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $13.32 and last traded at $13.45, with a volume of 726407 shares changing hands. The stock had previously closed at $13.75.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of Kailera Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 30th. Weiss Ratings assumed coverage on shares of Kailera Therapeutics in a report on Friday, August 14th. They set a "sell (d)" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $42.75.

Kailera Therapeutics Stock Down 2.2%

The stock has a fifty day moving average price of $17.53. The firm has a market capitalization of $1.74 billion and a P/E ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.35). Research analysts anticipate that Kailera Therapeutics, Inc. will post -3.89 EPS for the current fiscal year.

Institutional Trading of Kailera Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Atlas Venture Life Science Advisors LLC acquired a new position in shares of Kailera Therapeutics in the 2nd quarter valued at $113,923,000. Wellington Management Group LLP purchased a new position in shares of Kailera Therapeutics in the 2nd quarter valued at $64,308,000. Frazier Life Sciences Management L.P. acquired a new stake in Kailera Therapeutics during the 2nd quarter worth $24,233,000. Squarepoint Ops LLC acquired a new stake in Kailera Therapeutics during the 2nd quarter worth $993,000. Finally, Tidal Investments LLC purchased a new stake in Kailera Therapeutics in the second quarter valued at $309,000.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company's programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera's lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company's operations are centered on the development of therapies for global markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.